HBXIP is a novel regulator of the unfolded protein response that sustains tamoxifen resistance in ER+ breast cancer

Endocrine-therapy-resistant estrogen receptor–positive (ER+) breast cancer cells often exhibit an augmented capacity to maintain endoplasmic reticulum (EnR) homeostasis under adverse conditions. Oncoprotein hepatitis B X-interacting protein (HBXIP) is a known transcriptional coactivator that promote...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shenghong, Wang, Ranran, Wang, Xinyue, Guo, Xueling, Du, Yanyan, Guo, Xin, Zong, Xinlan, Zhu, Changhui, Zhou, Xiaolei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908272/
https://www.ncbi.nlm.nih.gov/pubmed/35093383
http://dx.doi.org/10.1016/j.jbc.2022.101644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908272/
https://www.ncbi.nlm.nih.gov/pubmed/35093383
http://dx.doi.org/10.1016/j.jbc.2022.101644

Ejemplares similares